TNGX

Tango Therapeutics (TNGX)

About Tango Therapeutics (TNGX)

Tango Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in discovering and delivering precision cancer medicines. It also identifies novel targets and develops new drugs directed at tumor suppressor gene loss in defined patient populations with high unmet medical need. The company was founded by Alan Ashworth, William G. Kaelin Jr., Jose Baselga, and Antoni Ribas in 2017 and is headquartered in Boston, MA.

Details

Daily high

$1.94

Daily low

$1.80

Price at open

$1.91

52 Week High

$12.02

52 Week Low

$1.72

Market cap

210.8M

Dividend yield

0.00%

Volume

92,219

Avg. volume

804,801

P/E ratio

-1.62

Tango Therapeutics News